SBIR/STTR Research Award

Point of Care Adult Stem Cell Isolation

Award identifier d30a7ea10ab7268ff1f1a0932a90c9fb38600ca64dbcaaa6c7d71b2f8c00928eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,863,609

Program and phase

SBIR · Phase II

Award year

2011

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AFFINERGY, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
YJQ6K1QMS488
Solicitation number
PA10-050
Topic code
NIAMS

Research abstract

DESCRIPTION (provided by applicant): Approximately 500,000 bone-grafting procedures are performed each year in the United States.5 Autologous iliac crest bone graft continues to be the gold standard, because it provides essential elements for bone formation: progenitor cells, an osteoconductive matrix, and osteoinductive molecules. However, iliac crest harvest is associated with a significant number of complications and often provides an inadequate volume of graft.6 To address these limitations, much work has been done to improve alternative grafts with better osteoconductive matrices and exogenous delivery of osteoinductive agents such as the bone morphogenetic proteins (BMPs).7 Currently there are only a few basic point-of-care devices to isolate progenitor cells, which are essential elements to foster bone healing. However, these devices are limiting because they are expensive and because they either enrich a non-specific cell population potentially diluting out desired cells or they enrich a specific cellpopulation using antibodies and consequently have safety concerns. Therefore, a safe, inexpensive device that could enrich adult stem cells from a bone marrow aspirate (BMA) or other tissue stroma at point-of-care would be of significant clinical benefit.In this phase II proposal, we will continue to develop a cell isolation device to enrich the multipotent subpopulation of cells in human bone marrow known as mesenchymal stem cells (MSCs). (*2)Furthermore, we will demonstrate versatility of the isolationdevice by showing that we can capture adult stem cells from adipose tissue. The advantage of adipose tissue is the availability of greater numbers of bone healing cells. We have identified and synthesized an MSC-binding peptide that can isolate adult stemcells from bone marrow and adipose tissue, and these isolated cells are multipotent. The MSC-binding peptide will be covalently attached to a solid support matrix and will form the functional core of the cell isolation device. The cells isolated will be captured and released using the prototype device, and different concentrations of cells will be tested in bone healing of a rat calvarial defect. An isolated pool of MSCs has the potential to serve key clinical functions in a range of indications includingosteoarthritis, Chron's disease and soft tissue repair such as tendon, ligament or wounds. This product will provide a safe and cost-effective point-of-care isolation system for the preparation of autologous cells. PUBLIC HEALTH RELEVANCE: Bone grafting is widely used in orthopedic surgery to treat fractures and large bone defects and to achieve spinal fusions. However, harvesting a bone graft from patients is associated with a significant number of complications and often provides an inadequate amount of tissue. While alternatives to bone grafts have shown promise, there is still room for considerable improvement. Therefore, a device, like the one proposed in this SBIR application, that could isolate adult stem cells efficiently and quickly in the operating room would be of significant clinical benefit in a number of clinical indications.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

75 SBIR/STTR records share this UEI (2005–2023). Reported award amounts total $59,804,968. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.